Vertex Pharmaceuticals Incorporated (LON: 0QZU)

Market Cap	89.50B
Revenue (ttm)	7.93B
Net Income (ttm)	-357.98M
Shares Out	n/a
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,273
Average Volume	3,837
Open	427.83
Previous Close	424.98
Day's Range	424.66 - 432.62
52-Week Range	290.87 - 446.29
Beta	0.39
RSI	52.70
Earnings Date	Feb 6, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underl...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1989
• Employees: 5,400
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QZU

Financial Performance

In 2023, Vertex Pharmaceuticals's revenue was $9.87 billion, an increase of 10.51% compared to the previous year's $8.93 billion. Earnings were $3.62 billion, an increase of 8.96%.

Financial numbers in USD